DBV Technologies invites you and your child to join the APTITUDE study to have your child tested!
APTITUDE is a Clinical Research Study to evaluate the performance of a ready to use experimental Patch Test (not approved by FDA yet) for the diagnosis of the delayed-onset type of Cow’s Milk Allergy in children.
This Study may help to identify substances (like cow’s milk) causing a delayed-type allergic reaction and may identify allergens not identified by blood testing or skin prick testing.
Can my child participate in the study?
Your child may be able to take part in this study if he/she:
- Is > 28 days to ≤ 24 months of age
- Has a history of symptoms that are consistent with delayed onset type of
- CMA, characterized by having either:
- Two or more gastrointestinal symptoms (vomiting, diarrhea, persistent distress/colic, regurgitation, constipation), that lasted at least 1 week within 1 month prior to screening or prior start of Cow’s milk protein elimination diet
- Blood in their stool
- Has any type of diet containing dairy products with cow’s milk protein (e.g., cow’s milk consumption, cow’s milk partial elimination, partially hydrolyzed milk) or started cow’s milk elimination diet not more than 4 weeks prior the screening visit.
There are other requirements that the study doctor will discuss with you to determine if your child is eligible to participate in this study.
How long is the study?
- If your child is able to participate in the study, then his or her participation may last up to approximately 3 months (including a potential screening period of up to 2 weeks).
If your child participates in the study, it is important that you:
- Attend all scheduled visits, phone calls, study requirements and complete an electronic daily diary
- Discuss with the study doctor at every visit how your child is feeling
If you think your child is able to participate, consider volunteering for the APTITUDE clinical research study.
To learn more about the study, please contact firstname.lastname@example.org.
You may also learn more about the study by visiting ClinicalTrials.Gov.
Sponsored by DBV Technologies